Arbor Biotechnologies has agreed to acquire Serendipity Biosciences, enhancing its genomic medicines portfolio. Financial terms were undisclosed
The acquisition will add Serendipity’s editing assets incl. Fanzor-based, IsrB-based & additional undisclosed programmable editing technologies to Arbor’s portfolio. These nuclease technologies will expand the therapeutic applications of Arbor’s genomic medicines
Furthermore, these CRISPR-Cas-based technologies will strengthen Arbor’s RT editing and both RNA & DNA-based exon/entire gene insertion in vivo using cutting properties (natural nickases), expanded genomic targeting as well as smaller sizes for delivery via AAV vectors and other size-constrained vehicles
Ref: Arbor Biotechnologies | Image: Arbor Biotechnologies
Related News:- Novartis to Acquire Mariana Oncology, Expanding its Radioligand Therapy Pipeline
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
